An observational study in Coronary Microvascular Dysfunction, Cardiotoxicity and Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Abramson Cancer Center at Penn Medicine · Observational
This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.
Patients with breast or lung cancer planned for treatment that includes pembrolizumab.
Exclusion Criteria:
Incidence of new abnormal myocardial blood flow reserve (MBFR)
Development of MBFR\<2
Time frame: 3 months
Incidence of major cardiovascular events
Composite measure including new/worsened heart failure, MI, stroke, myocarditis
Time frame: 3 months
Coronary calcium score
Change in PET derived Coronary Calcium (CAC) Score from baseline. CAC ranges from 0-400 agatson units; higher CAC indicates larger amounts of calcium are present in the coronary arteries.
Time frame: 3 month
All cause mortality
All cause mortality
Time frame: 3 months
Cardiovascular specific mortality
Cardiovascular specific mortality
Time frame: 3 months
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine